GleamWall
中文EN

AGTX Agentix Corp.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1603345 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY44.4%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-10,542.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets290,269.6%
Debt / equity—
Current ratio0.00x
Interest coverage-3.57x

Cash quality & payout

Operating cash flow / net income0.06x
Accruals ratio-9,875.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q22026-09-302027Q12026-06-302026Q4*2026-03-312026Q32025-12-312026Q22025-09-302026Q12025-06-302025Q4*2025-03-312025Q32024-12-31
Income statement
Revenue————————
R&D expense$4,191$16,635$0$0$25,079$100,000$90,349$23,287
SG&A expense$16,785$16,785$16,785$16,785$16,785$17,717$17,348$16,896
Operating income-$68,169-$95,504-$54,285-$67,463-$123,097-$200,342-$172,121-$96,815
Interest expense$23,158$22,170$20,917$13,804$24,159$21,226$13,895$11,295
Pretax income-$91,025-$117,674-$77,110-$78,595-$144,107-$185,824-$181,768-$143,894
Income tax$0$0$0$0$0$0$0$0
Net income-$91,025-$117,674-$77,110-$78,595-$144,107-$185,824-$181,768-$143,894
EPS (diluted)0.000.00—0.000.000.00—0.00
Weighted avg. shares (diluted)40.07M40.07M—40.07M40.07M40.07M—40.07M
Balance sheet
Cash & equivalents$1,312$38$771$6,396$5,601$4,412$4,477$8,273
Current assets$1,312$38$771$6,396$5,601$4,412$100,274$154,111
Total assets$1,312$38$771$6,396$5,601$4,412$100,274$154,111
Current liabilities$3.81M$3.71M$3.60M$3.50M$3.42M$3.28M$3.20M$3.07M
Total liabilities$3.81M$3.71M$3.60M$3.50M$3.42M$3.28M$3.20M$3.07M
Shareholders' equity-$3.81M-$3.71M-$3.60M-$3.50M-$3.42M-$3.27M-$3.10M-$2.92M
Shares outstanding40.07M40.07M40.07M40.07M40.07M40.07M40.07M40.07M
Cash flow statement
Operating cash flow-$3,522-$26,372$14,776-$7,938$3,004-$118,371-$43,058-$86,999
Investing cash flow$0$0$0$0$0$0$0$0
Financing cash flow$7,000$26,250$0$10,100$350$100,000$45,000$25,000

Free plan shows the latest 8 periods; Pro shows all 56 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.